180 Life Sciences Corp. and its subsidiary Cannbiorex Pharma Ltd. have entered into a Separation and Release Agreement with Sir Marc Feldmann, the former Co-Executive Chairman and Cannbiorex CEO, effective September 5, 2024. Under the agreement, the company will issue Feldmann 57,328 shares of common stock and options to purchase 20,000 shares at $1.95 per share with a two-year term.The agreement includes customary general releases between all parties, with Feldmann agreeing to confidentiality, non-disclosure, non-solicitation, non-disparagement, and cooperation covenants. Additionally, the company entered into an Indemnification Agreement with Feldmann, providing protection under Delaware law for his service to the company and its subsidiaries.Following the share issuance scheduled for September 9, 2024, the company's total outstanding common stock will be 1,026,930 shares.

180 Life Sciences Corp. and its subsidiary Cannbiorex Pharma Ltd. have entered into a Separation and Release Agreement with Sir Marc Feldmann, the former Co-Executive Chairman and Cannbiorex CEO, effective September 5, 2024. Under the agreement, the company will issue Feldmann 57,328 shares of common stock and options to purchase 20,000 shares at $1.95 per share with a two-year term.The agreement includes customary general releases between all parties, with Feldmann agreeing to confidentiality, non-disclosure, non-solicitation, non-disparagement, and cooperation covenants. Additionally, the company entered into an Indemnification Agreement with Feldmann, providing protection under Delaware law for his service to the company and its subsidiaries.Following the share issuance scheduled for September 9, 2024, the company's total outstanding common stock will be 1,026,930 shares.